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Acute cough due to viral upper respiratory tract infection (URI) is the most common form of
cough and accounts for tremendous expenditure on prescription and non-prescription cough
products worldwide. However, few agents have been shown in properly conducted clinical
trials to be effective for cough due to URI. The present study evaluated the effect of benzo-
natate 200 mg (B), guaifenesin 600 mg (G), their combination (B þG), and placebo (P) on
capsaicin-induced cough in 30 adult nonsmokers with acute URI. On 3 separate days within
a 7-day period, 1 h after ingesting randomly assigned study drug in a double-blind fashion,
subjects underwent capsaicin cough challenge testing, which involved inhalation of incre-
mental doubling concentrations of capsaicin until the concentration of capsaicin inducing 5
or more coughs (C5) was attained. Each subject received 3 of 4 possible study drugs. G
(pZ 0.01) but not B (pZ NS) inhibited cough-reflex sensitivity (log C5) relative to P. The
combination of BþG suppressed capsaicin-induced cough to a greater degree than B alone
(p< 0.001) or G alone (pZ 0.008). The mechanism by which the combination of BþG causes
a potentiation of antitussive effect remains to be elucidated. Our results suggest that BþG
may be an effective therapy for acute cough due to the common cold (URI).
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Cough is the most common complaint for which patients in
the United States seek medical attention.1 Acute cough
due to viral upper respiratory tract infection (URI) is the
most common form of cough and results in tremendous
financial expenditure on prescription and non-prescription.
Inhibition of cough-reflex sensitivity by benzonatate and guaifenesin in acute viral cough 903(over-the-counter) cough and cold products worldwide.
However, few of the currently available antitussive agents
have been shown, in properly conducted clinical trials, to
be effective in suppressing cough due to URI.2,3 The
narcotic opioids, such as codeine, have been demonstrated
to be ineffective for acute cough associated with URI.4,5 If
achieved, the antitussive effect of opioids often occurs at
the expense of troubling or intolerable side effects, such as
sedation or gastrointestinal disturbance.6
Guaifenesin, the glyceryl ether of guaiacol (a constit-
uent of guaiac resin from the wood of Guajacum officinale
Linne´), is a component of numerous cough and cold prod-
ucts available worldwide. Guaifenesin is termed an
expectorant since it is believed to alleviate cough discom-
fort by increasing sputum volume and decreasing its
viscosity (hydration hypothesis), thereby promoting effec-
tive cough.7 Guaifenesin remains the only expectorant
approved by the United States Food and Drug Administra-
tion (FDA).8 Despite its availability and common usage for
decades, few studies have evaluated the antitussive effect
of guaifenesin. A recently published trial demonstrated the
ability of guaifenesin to inhibit cough-reflex sensitivity in
subjects with acute URI, thus suggesting an antitussive as
well as expectorant action for the drug.9
Benzonatate, a long chain polyglycol derivative chemi-
cally related to procaine, is a peripherally-acting, oral
anesthetic agent whose mechanism of cough suppression is
believed to involve inhibition of pulmonary stretch recep-
tors.10 Studies performed soon after its approval in the
United States a half century ago showed benzonatate able
to inhibit experimentally-induced cough as well as to
suppress subjectively-measured pathological cough.11 No
further clinical trials of benzonatate have been published in
decades.
Given the urgent need for better cough suppressant
therapy, the goal of the present study was to evaluate, in
a prospective, randomized, double-blind, placebo-
controlled manner, the antitussive effect of the combina-
tion of benzonatate and guaifenesin in subjects with acute
URI. Cough-reflex sensitivity was measured by capsaicin
inhalation cough challenge. Capsaicin, the pungent extract
of red peppers, has been demonstrated in over two decades
of clinical experience to induce cough in a safe, dose-
dependent and reproducible manner,12,13 and therefore has
become an important tool for the assessment of the effect
of a pharmacological intervention on cough-reflex sensi-
tivity.14 The most commonly used endpoints of capsaicin
cough challenge are C2 and C5, the concentrations of
capsaicin inducing 2 or more, and 5 or more coughs,
respectively. The C5 has been shown to be the most




Subjects were otherwise healthy adult nonsmokers (life-
time nonsmokers or ex-smokers having abstained from
smoking >5 years) who developed symptoms consistent
with acute viral URI within 72 h of study enrollment.Suggestive symptoms included acute onset of cough, fever,
myalgias, rhinitis, nasal congestion, and sneezing. Symp-
toms suggestive of a possible bacterial infection, such as
sinus pain and purulent nasal discharge, excluded a subject
from enrollment. Other exclusion criteria included: history
of asthma or other pulmonary disease; use of medications
potentially affecting cough-reflex sensitivity (i.e., opiates
and angiotensin converting-enzyme (ACE) inhibitors); and
ingestion of the following types of medications within the
following time periods prior to study entry: short-acting
antihistamines (48 h); short-acting pseudoephedrine (12 h);
long-acting pseudoephedrine (24 h); non-steroid nasal
sprays (12 h); cough suppressants and expectorants (24 h).
Female subjects were required to be using adequate
contraception.
Study design
This was a randomized, double-blind, placebo-controlled
study of crossover design whose aim was to evaluate the
effect of a combination of benzonatate and guaifenesin,
relative to each individual drug and placebo, on cough-
reflex sensitivity to inhaled capsaicin in 30 otherwise
healthy volunteers with acute viral URI. Upon enrollment,
subjects were randomized to receive 3 of 4 possible study
drug combinations, one on each of 3 successive visits
occurring on 3 separate days within a 7-day period. The 4
possible study drug combinations included: benzonatate
200 mg (Inwood Laboratories, Commack, NY); guaifenesin
600 mg (BI Chemicals, Petersburg, VA); benzonatate
200 mgþ guaifenesin 600 mg; and placebo, all prepared as
identically-appearing capsules. Subjects underwent capsa-
icin cough challenge testing, to measure cough-reflex
sensitivity, 1 h after ingestion of study drug, administered
in a double-blind manner, on each of the 3 visits. The 1-h
pre-test interval was chosen to coincide with high plasma
levels of each study drug. The dosages of study drugs were
chosen to concur with current FDA-approved standards.
The FDA regulates the use of capsaicin in clinical trials and
required that no more than 3 successive doses (challenges)
be administered to a single subject in this study. Therefore,
the 4 study treatments were investigated with a (4,3,N )
balanced incomplete block design, in which each subject
received 3 of the 4 treatments according to a pre-
determined randomization scheme, over the course of 3
study visits. This study was approved by the Institutional
Review Board of Montefiore Medical Center, Bronx, New
York. All subjects provided written, informed consent.
Capsaicin cough challenge testing
Capsaicin was prepared and administered as previously
described.12 Briefly, a stock solution (0.01 M) of capsaicin
(Formosa Laboratories, Taiwan, ROC) was prepared and
subsequently diluted with physiological saline to yield serial
doubling concentrations ranging from 0.49 mM to 1000 mM.
Fresh dilutions were prepared on each day of testing.
Subjects inhaled single, vital-capacity breaths of
capsaicin aerosol administered via nebulizer (model 646;
DeVilbiss Health Care Inc., Somerset, PA) controlled by
a dosimeter (KoKo DigiDoser; nSpire Health Inc., Louisville,
904 P.V. Dicpinigaitis et al.CO). The nebulizer used in this study was modified in two
ways. First, an inspiratory flow regulator valve (RIFR; nSpire
Health Inc.) was added, which limited inspiratory flow to
0.5 L/s regardless of excessive inspiratory force, thereby
guaranteeing a constant and reproducible inspiratory effort
with each breath. Second, the straw and baffle assembly of
the nebulizer was welded in place, thereby eliminating the
variations in nebulizer output that occur when these
components are detached for washing and then reattached,
with resulting variable distances between the jet orifice
and straw. Given the nebulizer output of 1.007 mL/min,
duration of aerosol delivery was programmed at 1.2 s to
provide 0.02 mL aerosol per inhalation. Single breaths of
capsaicin were given in ascending order, with inhalations of
saline randomly interspersed to increase challenge blind-
ness, until the concentration inducing 5 or more coughs (C5)
was attained. Inhalations were delivered at 1-min intervals.
Subjects were unaware that the end point of the study was
the number of coughs induced.
Statistical analysis
A (4,3,N ) balanced incomplete block design was used, in
which each subject received 3 of the 4 possible treatments
according to a predetermined randomization scheme, over
the course of 3 study visits. Subjects were assigned to one
of 16 possible sequences of 3 of the 4 treatments, with the
following constraints: each of the 4 treatments was to be
received by the same number of subjects at any visit and
each of the 16 sequences was to appear 2 or 3 times in the
subject cohort.
Based on the observed variability in capsaicin cough
challenge data previously reported by the authors,9 sample
size estimates based on 80% power and 5% level of signifi-
cance in a crossover design yielded nZ 16 to detect a 40%
mean difference in log C5 before and after treatment. The
proposed sample size of 30 subjects in a (4,3,N ) balanced
incomplete block design as described above provided
approximately 20e24 observations per treatment. This
level of statistical power was deemed acceptable for this
initial exploratory study.
Log C5 and log C2 were analyzed using the analysis of















p value vs. benzonatate 0.298
a The differences in log-transformed concentrations between treatm
sequence, subject within sequence, period, and treatment.
b C5Z concentration of capsaicin inducing 5 or more coughs.with fixed terms for sequence, subject within sequence,
period, and treatment. Treatments were compared pair-
wise using Fisher’s Least Significant differences.Results
Thirty subjects (19 female, 11 male; mean age 42.2 14.0
[SD]) were enrolled and completed all 3 required study
visits. No significant adverse events were reported. Twenty-
three subjects (77%) were lifetime nonsmokers; 7 subjects
(23%) were distant ex-smokers (>5 years). The number of
subjects receiving each of the four possible study drugs
was: guaifenesin alone (nZ 22); benzonatate alone
(nZ 23); guaifenesinþ benzonatate (nZ 23); placebo
(nZ 22).
Characterizing the effect of study drug on cough-reflex
sensitivity (C5), mean log C5 was 0.43 with benzonatate
alone, 0.49 with placebo, 0.55 with guaifenesin, and 0.70
with guaifenesinþ benzonatate. The overall difference
among the treatments was statistically significant
(p< 0.001). In the pairwise comparisons, the log concen-
tration of the guaifenesin/benzonatate combination was
statistically significantly higher than either guaifenesin
alone (pZ 0.008) or benzonatate alone (p< 0.001). The log
concentration was statistically significantly higher than
placebo with both the guaifenesin/benzonatate combina-
tion (p< 0.001) and guaifenesin alone (pZ 0.010) [see
Table 1].
Effects of study drugs on cough-reflex sensitivity in
terms of C2 very closely mirrored, but were not identical to,
C5. In terms of mean log C2, the overall difference among
the treatments was statistically significant (pZ 0.007), as
were the pairwise comparisons between guaifenesin and
placebo (pZ 0.050); guaifenesin/benzonatate combination
and placebo (pZ 0.008); and, guaifenesin/benzonatate
combination and benzonatate alone (pZ 0.004). Mean
log C2 data demonstrated an effect of guaifenesin alone
compared to benzonatate alone (pZ 0.026) that was not
evinced by log C5 data. However, mean log C2 values did not
demonstrate a statistically significant difference between












ents were analyzed using an analysis of variance with factors for
Inhibition of cough-reflex sensitivity by benzonatate and guaifenesin in acute viral cough 905Carryover effects were tested using the analysis of
variance with terms for sequence, subject within sequence,
carryover, and treatment. In the analysis of C5, the p value
for the effect of carryover was 0.3739 and, in the analysis
of C2, the p value was 0.4280. Thus, carryover effects were
not statistically significant. A similar analysis was per-
formed to test the effect of visit number (i.e., time) and
was also found not to be significant.Discussion
We have demonstrated the ability of guaifenesin, and the
combination of guaifenesin and benzonatate, to inhibit
cough-reflex sensitivity in subjects with acute URI, whose
cough receptors are presumed to be transiently hypersen-
sitive.15,16 While the inhibitory effect, if any, of benzona-
tate alone on the capsaicin-induced cough reflex did not
achieve statistical significance in this study, guaifenesin
alone produced significantly greater cough-reflex inhibition
than placebo. In addition, the results of the study showed
a statistically significant increase in cough-reflex suppres-
sion when guaifenesin and benzonatate were used in
combination compared to either agent alone and to
placebo. These data suggest that benzonatate acts to
potentiate the antitussive efficacy of guaifenesin through
a mechanism as yet unknown. The antitussive effect of
guaifenesin using the capsaicin challenge model in subjects
with acute URI has been observed in an earlier trial,9 but its
potentiation by benzonatate has not been previously
reported.
Acute viral cough is often difficult to treat. Indeed, two
prospective placebo-controlled studies have shown the
narcotic opioid codeine to be clinically ineffective in
patients with acute cough due to URI.4,5 Recently published
cough management guidelines by the American College of
Chest Physicians (ACCP) did not recommend central cough
suppressants for cough due to URI, and furthermore, did not
recommend over-the-counter combination cold medica-
tions (with the exception of an older generation antihista-
mine-decongestant) for acute cough due to the common
cold, until randomized, controlled trials demonstrate their
efficacy.3
Cough-reflex sensitivity during acute viral URI appears
difficult to suppress in the laboratory. The authors, using
a PubMed search of the English language literature limited
to human trials, were unable to find a single study
demonstrating the ability of codeine or dextromethorphan,
probably the two most commonly used antitussive agents,
to inhibit capsaicin-induced cough in subjects with URI. The
present study confirms the results of an earlier trial that
showed a single, 400-mg dose of guaifenesin able to inhibit
capsaicin-induced cough in subjects with the common
cold.9 Thus, guaifenesin appears to have a dual mechanism
of action: as an antitussive, as well as an expectorant, for
which it is approved by the FDA. A recent study has also
demonstrated the ability of the anticholinergic bronchodi-
lator tiotropium to inhibit cough-reflex sensitivity to
inhaled capsaicin in subjects with URI.17
Given the need for better cough suppressant therapies
and the results of the present exploratory study, the
combination of guaifenesin and benzonatate merits furtherevaluation in clinical trials to assess its effect in acute as
well as other types of troublesome cough.
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